Literature DB >> 7497777

The effect of late-onset ventilator-associated pneumonia in determining patient mortality.

M H Kollef1, P Silver, D M Murphy, E Trovillion.   

Abstract

STUDY
OBJECTIVE: To determine whether the development of late-onset ventilator-associated pneumonia (VAP) is associated with an increased risk of hospital mortality.
DESIGN: Prospective cohort study.
SETTING: ICUs of two university-affiliated teaching hospitals. PATIENTS: Three hundred fourteen patients admitted to an ICU who required mechanical ventilation for greater than 5 days.
INTERVENTIONS: Prospective patient surveillance and data collection. MEASUREMENTS: The primary outcome measures were the development of late-onset VAP (ie, occurring > 96 h after intubation) and hospital mortality.
RESULTS: Late-onset VAP was observed in 87 patients (27.7%). Thirty-four (39.1%) patients with late-onset VAP died during hospitalization compared with 85 patients (37.4%) without late-onset VAP (relative risk, 1.04; 95% confidence interval [CI], 0.76 to 1.43). Twenty patients (6.4%) developed late-onset VAP due to a "high-risk" pathogen (ie, Pseudomonas aeruginosa, Acinetobacter sp, Xanthomonas maltophilia) with an associated mortality rate of 65%. Stepwise logistic regression analysis identified five variables as independent risk factors for hospital mortality (p < 0.05): an organ system failure index of 3 or greater (adjusted odds ratio [AOR], 3.4; 95% CI, 2.0 to 5.8; p < 0.001), having a nonsurgical diagnosis (AOR, 2.1; 95% CI, 1.3 to 3.6; p = 0.002), a premorbid lifestyle score of 2 or greater (AOR, 1.8; 95% CI, 1.1 to 2.9; p = 0.015), acquiring late-onset VAP due to a "high-risk" pathogen (AOR, 3.4; 95% CI, 1.2 to 10.0; p = 0.025), and having received antacids or histamine type-2 receptor antagonists (AOR, 1.7; 95% CI, 1.0 to 2.9; p = 0.034). Additionally, we found the occurrence of late-onset VAP due to high-risk pathogens to be the most important predictor of hospital mortality among patients developing VAP (AOR, 5.4; 95% CI, 2.8 to 10.3; p = 0.009).
CONCLUSIONS: Nosocomial pneumonia due to certain high-risk microorganisms is an independent risk factor for hospital mortality among patients requiring prolonged mechanical ventilation. We suggest that future investigations of late-onset VAP stratify patient outcomes according to the distribution of high-risk pathogens when reporting their results.

Entities:  

Mesh:

Year:  1995        PMID: 7497777     DOI: 10.1378/chest.108.6.1655

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  66 in total

Review 1.  Acute respiratory distress syndrome and nosocomial pneumonia.

Authors:  T T Bauer; A Torres
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

Review 2.  Prevention of nosocomial bacterial pneumonia.

Authors:  J L Vincent
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

3.  Outcome of postoperative pneumonia in the Eole study.

Authors:  Hervé Dupont; Philippe Montravers; Rémy Gauzit; Benoît Veber; Jean-Louis Pouriat; Claude Martin
Journal:  Intensive Care Med       Date:  2003-01-14       Impact factor: 17.440

4.  Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models.

Authors:  Molière Nguile-Makao; Jean-Ralph Zahar; Adrien Français; Alexis Tabah; Maité Garrouste-Orgeas; Bernard Allaouchiche; Dany Goldgran-Toledano; Elie Azoulay; Christophe Adrie; Samir Jamali; Christophe Clec'h; Bertrand Souweine; Jean-Francois Timsit
Journal:  Intensive Care Med       Date:  2010-03-16       Impact factor: 17.440

5.  Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria.

Authors:  E Raineri; L Crema; S Dal Zoppo; A Acquarolo; A Pan; G Carnevale; F Albertario; A Candiani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-04       Impact factor: 3.267

6.  Risk factors for late-onset ventilator-associated pneumonia in trauma patients receiving selective digestive decontamination.

Authors:  Marc Leone; Stéphane Delliaux; Aurélie Bourgoin; Jacques Albanèse; Franck Garnier; Ioana Boyadjiev; Francois Antonini; Claude Martin
Journal:  Intensive Care Med       Date:  2004-12-02       Impact factor: 17.440

7.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

8.  The microbial colonization profile of respiratory devices and the significance of the role of disinfection: a blinded study.

Authors:  Savita Jadhav; Tushar Sahasrabudhe; Vipul Kalley; Nageswari Gandham
Journal:  J Clin Diagn Res       Date:  2013-05-11

9.  Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia.

Authors:  Y-A Que; H Lazar; M Wolff; B François; P-F Laterre; E Mercier; J Garbino; J-L Pagani; J-P Revelly; E Mus; A Perez; M Tamm; J-J Rouby; Q Lu; J Chastre; P Eggimann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-24       Impact factor: 3.267

10.  Pseudomonas aeruginosa induces localized immunosuppression during pneumonia.

Authors:  Maureen H Diaz; Ciara M Shaver; John D King; Srinidhi Musunuri; Jeffrey A Kazzaz; Alan R Hauser
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.